Angelman Syndrome: Clinical Trials

10 trials for Angelman Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 10 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 210Completed 6, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1
Phase 13Active not recruiting 1, Completed 1, Recruiting 1
Phase 31Completed 1

Follow Angelman Syndrome: new trials by email Literature Review of Angelman Syndrome trials Research Report on Angelman Syndrome

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
MVX-220 - Angelman Syndrome
Phase 1 / Phase 2RecruitingMavriX Bio, LLC122025-10-292026-07-24
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
No intervention, GTX-102 - Angelman Syndrome
Phase 2TerminatedUltragenyx Pharmaceutical Inc552025-10-132026-11-03
A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
Alogabat - Angelman Syndrome
Phase 2CompletedHoffmann-La Roche482023-07-272025-12-04
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
NNZ-2591 - Angelman Syndrome
Phase 2CompletedNeuren Pharmaceuticals Limited172022-07-122025-01-31
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
ION582 - Angelman Syndrome
Phase 1 / Phase 2Active not recruitingIonis Pharmaceuticals, Inc.712021-12-222026-11-17
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome
GTX-102 - Angelman Syndrome
Phase 1 / Phase 2CompletedUltragenyx Pharmaceutical Inc742020-02-242026-01-09
A Study in Adults and Adolescents With Angelman Syndrome (STARS)
OV101 Regimen 1, OV101 regimen 2, Placebo - Angelman Syndrome
Phase 2CompletedHealx AI882016-01-012025-08-03
An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
EPI-743 - Autism Spectrum Disorder
Phase 2WithdrawnEdison Pharmaceuticals Inc2014-10-312022-01-21
Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome
MINOCYCLINE, PLACEBO (for Minocycline) - Angelman Syndrome
Phase 2CompletedPuerta de Hierro University Hospital322014-01-012015-10-21
A Trial of Levodopa in Angelman Syndrome
Levodopa, Placebo Oral Capsule - Angelman Syndrome
Phase 2 / Phase 3CompletedWen-Hann Tan672011-01-012020-07-15

Narrower conditions

Autism Spectrum Disorder (1)  ·  Autistic Disorder (1)  ·  Mitochondrial Diseases (1)  ·  Rare Diseases (1)  ·  Rett Syndrome (1)  ·  cyclopia sequence (1)

Broader conditions

Abnormalities, Multiple (10)  ·  Central Nervous System Diseases (10)  ·  Chromosome Disorders (10)  ·  Congenital Abnormalities (10)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10)  ·  Genetic Diseases, Inborn (10)  ·  Imprinting Disorders (10)  ·  Movement Disorders (10)  ·  Nervous System Diseases (10)  ·  Child Development Disorders, Pervasive (1)  ·  Disease Attributes (1)  ·  Genetic Diseases, X-Linked (1)  ·  Heredodegenerative Disorders, Nervous System (1)  ·  Intellectual Disability (1)  ·  Mental Disorders (1)

Interventions

Levodopa (1)  ·  Minocycline (1)  ·  alpha-tocotrienol quinone (1)  ·  carbidopa, levodopa drug combination (1)  ·  cyclo-L-glycyl-L-2-allylproline (1)  ·  gaboxadol (1)

Sponsors

Ultragenyx Pharmaceutical Inc (2)  ·  Edison Pharmaceuticals Inc (1)  ·  Healx AI (1)  ·  Hoffmann-La Roche (1)  ·  Ionis Pharmaceuticals, Inc. (1)  ·  MavriX Bio, LLC (1)  ·  Neuren Pharmaceuticals Limited (1)  ·  Puerta de Hierro University Hospital (1)  ·  Wen-Hann Tan (1)

Countries

United States (7)  ·  Australia (4)  ·  France (4)  ·  Israel (4)  ·  Italy (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Germany (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Canada (1)  ·  Portugal (1)

Top investigators

Amit Rakhit, MD, MBA (1)  ·  Anne Slavotinek, MD (1)  ·  Carlos A. Bacino, MD (1)  ·  Cary Fu, MD (1)  ·  James Shaw (1)  ·  Logan Wink, M.D (1)  ·  Lynne M. Bird, MD (1)  ·  Steven A. Skinner, MD (1)  ·  Wen-Hann Tan, BMBS (1)

Results publications

PMID 30126448, PMID 33443117, PMID 36947593